KyungDong Pharm home
Prescription Medicines

Nacodrin nasal spray

Product Category
Allergic rhinitis treatment
Active Ingredients
mometasone furoate
Appearance
White or nearly white, opaque suspension in a spray bottle
Reimbursement Code
648102921
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
Of 1mL
- Active ingredient: Mometasone furoate (USP)----0.5mg
- Additives (preservatives): Benzalkonium chloride (EP)----0.2mg
- Other additives: concentrated glycerin, dispersible cellulose, citric acid hydrate, sodium citrate hydrate, purified water, polysorbate 80

2. Effectiveness
1. Adults and children over 2 years of age: Seasonal allergic rhinitis and year-round rhinitis. In patients who have had symptoms of moderate to severe seasonal allergic rhinitis, preventive therapy can be started 2 to 4 weeks before the scheduled start of the pollen season (scheduled allergen exposure date).
2. Adults over 18 years of age: Nasal polyps
3. Adults and adolescents over 12 years of age: Acute rhinosinusitis without severe bacterial infection

3. Dosage and dosage
1. Allergic rhinitis
Each press of the nebulizer releases approximately 100 mg of mometasone furoate suspension, which contains 0.05 mg of mometasone furoate (as anhydrous).
To ensure uniform spraying, test spray 10 times before use. If the sprayer has not been used for more than 14 days, test spray must be repeated twice before the next use.
1) Adults (including the elderly) and youth over 12 years of age:
Generally, spray twice a day into each nostril (total daily dose of 0.2 mg). When symptoms are alleviated, the frequency of spraying can be reduced to once per nostril as a maintenance dose (total daily dose of 0.1 mg).
If symptoms are not alleviated, the dose can be increased up to 4 times in each nostril once a day (total dose of 0.4 mg per day), and it is recommended to reduce the dose when symptoms are alleviated. It must be used regularly to obtain maximum therapeutic benefit.
2) Children aged 2 to 11 years:
Generally, spray once a day into each nostril (total daily dose of 0.1 mg).

2. Nasal polyps
Generally, spray twice per day into each nostril (total daily dose of 0.2 mg).
If symptoms are not alleviated after 5 to 6 weeks, the dose can be increased to spraying twice a day for each nostril (total dose of 0.4 mg per day). It is recommended to reduce the dose when symptoms are alleviated.
If symptom relief does not occur even after administration twice a day for 5 to 6 weeks, consider another treatment.
There are no studies using this drug for more than 4 months to treat nasal polyps.

3. Acute rhinosinusitis
Generally, spray twice a day, twice per nostril (total daily dose of 0.4 mg).

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or its components
2) Patients with untreated local infection in the nasal mucosa
3) Patients who have recently undergone nasal surgery or have a nasal disease, septal ulcers, or trauma to the nose (considering the effect of corticosteroids on wound healing, these patients should not use nasal corticosteroids until healing occurs).
4) Infants under 2 years of age

2. Administer with caution to the following patients.
1) Patients with active or latent tuberculosis of the respiratory tract, untreated systemic fungal, bacterial, viral infection, or herpes simplex in the eyes
2) Patients with repetitive nosebleeds (bleeding may worsen)
3) Patients who may be infected with chickenpox or measles (refer to ‘General Precautions’)
4) Patients with unilateral nasal polyps, cystic fibrosis-related nasal polyps, and nasal polyps that completely block the nasal cavity (the effect of this drug has not been studied in these patients. Unilateral nasal polyps with abnormal or irregular shapes, especially those that are bleeding or ulcerated, should be evaluated in more detail.)
5) Pregnant women, women who may be pregnant, or lactating women

3. Adverse reactions
1) Allergic rhinitis: In clinical trials conducted in the United States and other countries, a total of 3,210 adult and adolescent patients aged 12 years or older were administered this drug at a dose of 50 to 800 μg per day. Most of the patients (n = 2,103) received a dose of 200 μg per day. In clinical trials conducted in the United States and other countries, a total of 990 pediatric patients (ages 3 to 11) were administered this drug at a dose of 25 to 200 μg per day. Most of the patients (n = 720) received a dose of 100 μg per day. A total of 513 adult and pediatric patients were treated for more than 1 year. The general incidence of adverse reactions was similar in the placebo-treated group and this drug-treated group. Additionally, there were no significant differences based on age, gender, or race. More than 3% of patients discontinued medication due to adverse reactions. This is a similar frequency to that in the placebo group and the active comparison group.
In clinical trials in which this drug was administered at a dose of 200 μg per day to adult and adolescent patients aged 12 years or older and clinical trials in which pediatric patients aged 3 to 11 years were administered a dose of 100 μg per day, adverse reactions that occurred in more than 5% of cases and were reported more frequently than in the placebo group (regardless of whether they were related to drug administration) are listed in Table 1 below.

<Table 1> ※ Please check the attached document for details.

(1) Other adverse reactions that occurred in 2% to less than 5% of adult and adolescent patients (12 years of age or older) administered a dose of 200 μg of this drug and were more frequent than those in the placebo group: arthralgia, asthma, bronchitis, chest pain, conjunctivitis, diarrhea, indigestion, earache, flu-like symptoms, muscle pain, nausea, rhinitis
(2) Other adverse reactions that occurred in more than 2% but less than 5% of pediatric patients (3 to 11 years of age) administered a dose of 100 μg of this drug and were more frequent than those in the placebo group: diarrhea, nasal irritation, otitis media, wheezing.
(3) In a clinical trial involving 56 patients (28 in the treatment group and 28 in the placebo group) administered to pediatric patients aged 2 to 5 years at a dose of 100 μg per day, adverse reactions reported more frequently than in the placebo group (regardless of whether or not they were related to drug administration): upper respiratory tract infection (7% vs. 0%, respectively)
(4) Other adverse reactions that occurred in more than 2% but less than 5% of pediatric patients aged 2 to 5 years receiving a dose of 100 μg of this drug and were more frequent than those in the placebo group: trauma to the skin
(5) In clinical trials conducted in Japan, the adverse reactions that occurred when this drug was administered to 2,053 adults and children are shown in Table 2 below.

<Table 2> ※ Please check the attached document for details.

2) Nasal polyps: Nasal ulcers and nasal and oral candidiasis were rarely reported in groups treated with this drug for more than 4 weeks.
The overall incidence of adverse reactions in clinical patients with nasal polyps was similar to that of placebo and was similar to the adverse reactions observed in patients with allergic rhinitis. Adverse reactions reported in nasal polyp clinical trials are presented in Table 3 below.

<Table 3> ※ Please check the attached document for details.

3) Acute rhinosinusitis: In clinical trials targeting patients with acute rhinosinusitis, the overall incidence of adverse reactions was similar to placebo and similar to that of other approved indications. Adverse reactions reported in acute rhinosinusitis clinical trials are presented in Table 4 below.

<Table 4> ※ Please check the attached document for details.

The most frequently occurring adverse reaction, nosebleeds, occurred with approximately the same frequency in patients treated with this drug (2.9-3.7%) and placebo-treated patients (2.6%).
4) In rare cases, immediate hypersensitivity reactions such as bronchospasm and difficulty breathing may occur after intranasal administration of this drug. In very rare cases, anaphylaxis symptoms (difficulty breathing, systemic flushing, angioedema, hives, etc.) may appear, so observe thoroughly and if abnormalities are recognized, discontinue administration and take appropriate treatment.
5) In particular, systemic effects may occur when high doses of intranasal corticosteroids are administered over a long period of time.
6) If symptoms or signs of severe bacterial infection (fever, severe persistent unilateral facial pain and toothache, facial swelling in or around the eyes, or worsening of symptoms after initial improvement) are observed, consult a doctor immediately.
7) In post-marketing surveillance, burning and inflammation of the nose, hypersensitivity reaction, and angioedema were reported, and nasal septum perforation was rarely reported. Abnormalities in taste and smell have also been reported very rarely. Blurred vision was reported at an unknown frequency.

4. General precautions
1) No signs of atrophy of the nasal mucosa were evident for 12 months after treatment with this drug. Additionally, this drug showed a tendency to restore the nasal mucosa to something close to a normal tissue phenotype. As with all long-term treatment, patients using this drug for several months or more should be examined regularly to check for incidental changes in the nasal mucosa. If localized fungal infection occurs in the nasal cavity or pharynx, administration of this drug may be discontinued or appropriate treatment may be required. If nasopharyngeal irritation persists, treatment with this medication may need to be discontinued.
2) Since non-symptoms are alleviated in most patients, simultaneous use of appropriate adjunctive treatments can additionally lead to relief of other symptoms, especially eye symptoms.
3) There is no evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression due to long-term administration of this drug. However, special caution is required in patients who switch to this drug after taking systemic active corticosteroids for a long period of time. Discontinuation of systemic corticosteroids in such patients may result in adrenal insufficiency for several months until HPA axis function is restored. If these patients exhibit signs and symptoms of adrenal insufficiency, systemic corticosteroid administration should be resumed, and other forms of treatment and appropriate measurement methods should be established.
4) While switching from systemic corticosteroids to this drug, some patients may experience withdrawal symptoms from systemically active corticosteroids (e.g., joint and muscle pain, fatigue, initial depression) despite relief of non-symptoms, but it is recommended to continue using this drug. This change to other medications may reveal pre-existing allergic conditions such as allergic conjunctivitis and eczema that were previously suppressed by systemic corticosteroid treatment.
5) Patients receiving corticosteroids and strong immunosuppressants should be warned about the risk of exposure to certain infections (e.g., chickenpox, measles) and the importance of seeking medical advice if exposed to such infections. In particular, if you become infected with chickenpox or measles while taking this medicine, it may lead to a fatal outcome, so the following precautions are required.
(1) Before administering this drug, check the history of chickenpox or measles and whether or not you have been vaccinated.
(2) For patients without a history of chickenpox or measles, provide sufficient consideration and observation to prevent infection with chickenpox or measles as much as possible. If infection is suspected or infected, immediately receive a medical examination, receive guidance, and take appropriate measures.
(3) Be aware that even in patients who have a history of chickenpox or measles and have been vaccinated, there is a possibility that chickenpox or measles may occur while taking this drug.
6) Full expected effects may not appear within the first 48 hours.
7) When nasal corticosteroids are administered to pediatric patients, growth may be delayed (see ‘Administration to children’). In clinical trials of this drug, Candida albicans infections of the nose or pharynx were very rare. If such infection occurs, use of this drug should be discontinued and replaced with appropriate topical or systemic therapy.
8) This drug was administered at 200 ㎍ per day to evaluate whether it caused glaucoma and cataracts using intraocular pressure measurement and slit lamp testing through a 12-week controlled test and a 12-month uncontrolled test. This drug was administered to 141 patients for 12 weeks, and there was no significant difference in average intraocular pressure when compared with 141 placebo-treated patients. No patient receiving this drug had a significant increase in intraocular pressure or developed cataracts during the 12-week treatment period. Additionally, no significant changes in intraocular pressure were observed in the 139 patients who took this drug for 12 months, and no cataracts occurred. Nonetheless, intranasal or inhaled corticosteroids have been associated with the development of glaucoma and cataracts, so patients should be closely monitored for changes in vision or a history of glaucoma or cataracts.
Additionally, visual disturbances may be reported with systemic and topical (including intranasal, inhaled, and intraocular) corticosteroid use. If patients experience symptoms such as blurred vision or other visual impairment, they should consider seeing an ophthalmologist to determine possible causes of visual impairment, including rare conditions such as cataracts, glaucoma, or central serous chorioretinopathy (CSCR), which have been reported after systemic and topical corticosteroid use.
9) If nasal corticosteroids are used in excessive amounts, systemic corticosteroid effects such as hyperadrenocorticism or suppression of adrenal function may occur. In these cases, the use of topical corticosteroids should be gradually discontinued with measures corresponding to the withdrawal process of oral steroids.
10) The effect of this drug on unilateral nasal polyps, cystic fibrosis-related nasal polyps, and nasal polyps that completely block the nasal cavity has not been studied. Abnormal or irregularly shaped unilateral nasal polyps, especially those that are bleeding or ulcerated, should be evaluated in more detail.
11) Cases of nasal septum perforation and increased intraocular pressure have been rarely reported after using nasal corticosteroids.
12) Athletes should be careful because the active ingredient in this drug may cause a positive reaction in a doping test.
13) Be careful because the preservative benzalkonium chloride may cause nasal mucosal edema and may cause breathing difficulties if administered for a long period of time.

5. Interaction
1) When using with systemic corticosteroids, see general precautions 4. 3) ~ 6).
2) When this drug was administered in combination with loratadine, it did not affect the plasma concentration of loratadine or the main metabolism of loratadine. The blood concentration of this drug was not detected (a quantitative method with a limit of quantitation of 50 pg/mL was used), and the combination therapy was found to be well tolerated.
3) Mometasone furoate is metabolized through CYP3A4. Co-administration of CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat-containing products, etc.) may increase blood corticosteroid concentrations and potentially increase the risk of systemic corticosteroid side effects. Co-administration should be avoided unless the benefits outweigh the increased risks. If coadministered, systemic corticosteroid side effects should be carefully monitored.

6. Administration to pregnant and lactating women
1) There are no appropriate studies in pregnant women. As with other nasal corticosteroids, this drug should be administered to pregnant or lactating women only when the potential benefits to the mother are judged to outweigh the potential risks to the mother, fetus, and infant.
2) Infants born to mothers who received corticosteroids during pregnancy should be carefully monitored for adrenal insufficiency.

7. Administration to children
1) Clinical trials on the administration of nasal corticosteroids to pediatric patients showed that growth rate may be reduced. These results, obtained in the absence of evidence for hypothalamic-pituitary-adrenal (HPA) axis suppression, appear to suggest that growth velocity is a more sensitive measure of systemic corticosteroid exposure than commonly used tests of HPA axis function. The long-term effects of reduced growth rate, including effects on final adult height, are not known. The potential for compensatory growth upon discontinuation of nasal corticosteroid treatment has not been adequately studied. The growth of pediatric patients receiving nasal corticosteroids, including this drug, should be monitored regularly. The clinical effects achieved with long-term administration and the safety and effectiveness of other optional non-corticosteroid drug treatments should be considered compared with the potential for effects on growth. To minimize the systemic effects of nasal corticosteroids, including this drug, the lowest effective dose should be prescribed for each patient.
A clinical trial was conducted in which 720 patients aged 3 to 11 years were administered this drug (total daily dose of 100 ㎍). A clinical trial was conducted in which this drug (total daily dose of 100 ㎍) was administered to 28 patients aged 2 to 5 years to evaluate its safety. Safety and efficacy in pediatric patients younger than 2 years of age have not been established.
A one-year clinical trial was conducted in pediatric patients (3 to 9 years of age) to determine the effect of this drug (total daily dose of 100 μg) on growth rate. Compared to placebo, the effect of administration of this drug on growth rate did not show statistical significance. There was no clinical evidence of HPA axis suppression after 30 minutes of cosyntropin infusion. The possibility of this drug causing growth inhibition cannot be ruled out in susceptible patients or when administered at high doses.
2) The effect of this drug on nasal polyps in adolescents and children under 18 years of age has not been studied.
3) The effect of this drug on rhinosinusitis in children under 12 years of age has not been studied.

8. Administration to elderly people
In general, elderly people have reduced physiological function, so administer with caution while observing the patient's condition.

9. Treatment in case of overdose
Since the systemic bioavailability of this drug is less than 1% (using a highly sensitive quantitative method with a lowest detection limit of 0.25 pg/mL), no special treatment is required in case of overdose other than observation after administration of an appropriate dose. However, in general, when excessive amounts of corticosteroids are inhaled or orally administered, suppression of HPA axis function may occur.

10. Application precautions
1) Before administering the initial dose, shake the container well and test spray the pump 10 times (until uniform spraying is confirmed). If the pump has not been used for more than 14 days, test spray twice in advance. Shake the container well before each use. This medicine should be discarded after spraying the number of times indicated on the package or 2 months after first use.
2) Be careful not to spray this drug directly into the eyes or nasal septum and use it only as an intranasal spray.

11. Storage and handling precautions
Keep out of reach of children.

12. Others
The effects on driving function and machine operation are unknown.

5. How to save
Airtight container, stored at room temperature (2~25℃)

6. Packaging unit
18g (140 times)/bottle

7. Expiration date
24 months from date of manufacture

Product Updates

Total 3items

No.Product NameDetailsDate of ChangeDownload
3Nacodrin nasal sprayPrecautions for use2021.01.07PDFPrecautions for use_Mometasone furoate single agent (spray) change attached.pdf
2Nacodrin nasal sprayNarcodrin Nasal Spray (Dosage, Instructions for Use...2013.01.30HWPNarcodrin Nasal Spray_Permission changes.hwp
1Nacodrin nasal sprayNarcodrin Nasal Spray (efficacy, dosage, usage...2012.12.31HWPNarcodrin Nasal Spray_Permission Change Order.hwp